Non-Tuberculous Mycobacterial Pulmonary Disease Prevalence Status in China
Chunfa Liu,Yimeng Song,Wencong He,Dongxin Liu,Ping He,Jingjing Bao,Xinyang Wang,Xichao Ou,Bing Zhao,Jiale Fan,Qian Cheng,Yang Zhou,Yuanyuan Song,Yang Zheng,Hui Xia,Shengfen Wang,Yanming Li,Yanlin Zhao
DOI: https://doi.org/10.21203/rs.3.rs-47871/v1
2020-07-30
Abstract:Abstract Introduction: The information on the pulmonary disease caused by non-tuberculosis mycobacterium (NTM) in China is limited, mainly based on local or regional studies. Methods: Retrospective study involving 72 tuberculosis clusters provided sputa of enrolled presumptive cases for mycobacterial and drug-susceptibility testing in 31 provinces of Chinese mainland. Minimal inhibitory concentrations (MICs) test was used to measure the susceptibility of NTM isolates. Results: Of 4917 mycobacterial isolates cultured, 317 (6.4%, 95% confidence interval [CI], 5.8 to 7.2) isolates were confirmed as NTM, among 207 (12.1%, 95% CI, 10.6 to 13.8) isolates were detected from the southeastern region with the highest NTM prevalence. Slow growing mycobacteria (SGM) contributed 93.3% (95% CI, 76.4 to 98.8) and 56.1% (95% CI, 50.1 to 61.9) in northern and southern China, respectively. A total of 29 species were detected, the three most frequently isolated NTM belonged to Mycobacterium abscessus complex (36.0%, 95% CI, 33.3 to 38.7), Mycobacterium avium-intracellulare complex (34.1%, 95% CI, 29.1 to 39.5), Mycobacterium kansasii (9.8%, 95% CI, 8.1 to 11.4), respectively. Clarithromycin and amikacin were showed lower resistant rates to NTM in vitro. Conclusions: The southeastern region should be paid more attention to NTM pulmonary disease. More rapid growing mycobacteria (RGM) were present in southern China than the northern (P < 0.001). Considering clear correlations between in vitro activity and the in vivo outcomes of treatment, macrolides and amikacin were recommended in NTM treatment in China.